De Simone C, Ferrazzi M, Bitonti F, Falciano M, Tzantzoglou S, Delia S, Sorice F
Insegnamento Malattie Infettive, Università dell'Aquila degli Abruzzi, L'Aquila, Italy.
Immunopharmacol Immunotoxicol. 1988;10(4):437-41. doi: 10.3109/08923978809006447.
3'-azido-3'-deoxythymidine (AZT) was administered orally to 8 AIDS patients at a dose of 100 mg every 6 hours for 14 days. On days 8 - 14 the patients were also given 1 g inosine-pranobex (INPX) every 6 hours. On day 7, while the subjects were taking AZT alone and on day 14 while they were receiving AZT + INPX, blood samples were obtained over a 6-hour dosing interval for measurement of AZT by a specific AZT radioimmunoassay. AZT levels on day 14 were significantly higher than the corresponding levels on day 7, resulting in a 2-fold increase of the area under the serum concentration-time curve (AUC) and a prolongation of the mean half-life of AZT (44 to 70 min) during the INPX treatment. INPX is an immunomodulatory drug with an inhibitory effect on HIV. The potential advantages of a combined treatment AZT + INPX are: 1) need for lower dose of AZT for maintaining a therapeutic anti-retroviral level; 2) a longer interval period between AZT treatments; 3) a potential to enhance immunological response resulting from INPX treatment; 4) reduced costs of care for patients.
3'-叠氮-3'-脱氧胸苷（AZT）以每6小时100毫克的剂量口服给予8名艾滋病患者，持续14天。在第8 - 14天，患者还每6小时服用1克异丙肌苷（INPX）。在第7天，当受试者单独服用AZT时，以及在第14天，当他们接受AZT + INPX治疗时，在6小时的给药间隔内采集血样，通过特定的AZT放射免疫测定法测量AZT。第14天的AZT水平显著高于第7天的相应水平，导致血清浓度-时间曲线下面积（AUC）增加了2倍，并且在INPX治疗期间AZT的平均半衰期延长（从44分钟延长至70分钟）。INPX是一种对HIV有抑制作用的免疫调节药物。AZT + INPX联合治疗的潜在优势有：1）维持治疗性抗逆转录病毒水平所需的AZT剂量较低；2）AZT治疗之间的间隔期更长；3）有增强INPX治疗引起的免疫反应的潜力；4）降低患者的护理成本。
